Vanda Pharmaceuticals
VNDA
140 hedge funds and large institutions have $672M invested in Vanda Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 31 reducing their positions, and 11 closing their positions.
227% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 11
84% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 31
57% more call options, than puts
Call options by funds: $27M | Put options by funds: $17.2M
55% more capital invested
Capital invested by funds: $434M → $672M (+$238M)
22% more funds holding
Funds holding: 115 → 140 (+25)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$16.8M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$13.5M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$9.15M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.31M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$7.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$34.5M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$24M |
| 3 |
PC
Paulson & Co
New York
|
-$22.7M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$9.08M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$5.19M |
VNDA Hedge Fund Activity: Q3 2016 in Review
140 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2016, worth a combined $672M — up 55% from $434M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new VNDA positions and 11 closed out — a net gain of 25 holders — while 57 added to existing stakes and 31 trimmed.
The largest buyer was Millennium Management, adding an estimated $16.8M. The largest seller was Deerfield Management, cutting an estimated $34.5M.
- 140 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2016, up from 115 in Q2 2016.
- Funds reported $672M of Vanda Pharmaceuticals stock for Q3 2016, up 55% quarter-over-quarter.
- 36 funds opened new Vanda Pharmaceuticals positions in Q3 2016 and 11 closed out, a net change of +25 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2016 was Millennium Management, an estimated $16.8M added.
- The largest Vanda Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $34.5M sold.
Based on aggregated 13F filings for Q3 2016.